Ignite Creation Date:
2025-12-25 @ 1:14 AM
Ignite Modification Date:
2025-12-25 @ 11:24 PM
Study NCT ID:
NCT03422393
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-05
First Post:
2018-01-30
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Sponsor:
Michael Choi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-05-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-08
Completion Date Type:
ESTIMATED
First Submit Date:
2018-01-30
First Submit QC Date:
None
Study First Post Date:
2018-02-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-03
Last Update Post Date:
2024-07-05
Last Update Post Date Type:
ACTUAL